Vivos Therapeutics, Inc. (VVOS) Analyst Estimates Annual - Discounting Cash Flows
VVOS
Vivos Therapeutics, Inc.
VVOS (NASDAQ)
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
Number of Analysts 2 1 1 1 1 1 1
Estimated Revenue
Low 19.1 15.28 15.18 13.96 16.28 17.3 12.94
Average 19.17 15.3 15.2 13.98 16.55 17.3 12.94
High 19.23 15.32 15.22 14 16.82 17.3 12.94
Estimated EBITDA
Low -17.55 -13.98 -13.89 -12.78 -15.9 -16.33 -12.22
Average -17.49 -13.96 -13.87 -12.76 -15.64 -16.33 -12.22
High -17.43 -13.94 -13.85 -12.74 -15.39 -16.33 -12.22
Estimated EBIT
Low -17.91 -14.27 -14.17 -13.04 -16.3 -16.75 -12.53
Average -17.85 -14.25 -14.16 -13.02 -16.04 -16.75 -12.53
High -17.79 -14.23 -14.14 -13 -15.78 -16.75 -12.53
Estimated Net Income
Low -5.82 -7.14 -10.16 -52.87 -33 -27.44 -18.29
Average -4.67 -7.13 -10.14 -52.78 -32.31 -27.44 -18.29
High -3.51 -7.12 -10.12 -52.7 -31.63 -27.44 -18.29
Estimated SGA Expenses
Low 32.53 26.02 25.86 23.78 28.76 30.56 22.86
Average 32.64 26.06 25.89 23.81 29.24 30.56 22.86
High 32.75 26.09 25.92 23.84 29.71 30.56 22.86
Estimated EPS
Low -1.16 -1.42 -2.02 -10.53 -27.06 -22.5 -15
Average -0.93 -1.42 -2.02 -10.52 -26.5 -22.5 -15
High -0.7 -1.42 -2.02 -10.5 -25.94 -22.5 -15
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us